MC4 receptor antagonists

A potential treatment for cachexia

Alan C. Foster, Chen Chen, Stacy Markison, Daniel Marks

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Cachexia (involuntary weight loss) is a devastating syndrome associated with many chronic diseases including cancer, and heart, lung, kidney and liver failure. There are currently no effective treatments capable of reversing the loss of lean body mass that is believed to be a major contributor to morbidity and mortality in these chronic diseases. Recent findings strongly indicate that blockade of central melanocortin signaling through the MC4 receptor subtype attenuates cachexia. This review summarizes the evidence supporting the role of MC4 receptors in cachexia, and highlights the progress achieved in the development of small-molecule MC4 antagonists, which have recently proved to be effective in animal models of cachexia. MC4 antagonists are an attractive therapeutic approach for cachexia that may ameliorate the loss of lean body mass in cachectic patients.

Original languageEnglish (US)
Pages (from-to)314-319
Number of pages6
JournalIDrugs
Volume8
Issue number4
StatePublished - Apr 2005

Fingerprint

Receptor, Melanocortin, Type 4
Cachexia
Chronic Disease
Melanocortins
Therapeutics
Liver Failure
Liver Neoplasms
Renal Insufficiency
Weight Loss
Lung Neoplasms
Animal Models
Heart Failure
Morbidity
Mortality

Keywords

  • Body-weight regulation
  • Cachexia
  • MC4 receptor
  • Melanocortins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Foster, A. C., Chen, C., Markison, S., & Marks, D. (2005). MC4 receptor antagonists: A potential treatment for cachexia. IDrugs, 8(4), 314-319.

MC4 receptor antagonists : A potential treatment for cachexia. / Foster, Alan C.; Chen, Chen; Markison, Stacy; Marks, Daniel.

In: IDrugs, Vol. 8, No. 4, 04.2005, p. 314-319.

Research output: Contribution to journalArticle

Foster, AC, Chen, C, Markison, S & Marks, D 2005, 'MC4 receptor antagonists: A potential treatment for cachexia', IDrugs, vol. 8, no. 4, pp. 314-319.
Foster AC, Chen C, Markison S, Marks D. MC4 receptor antagonists: A potential treatment for cachexia. IDrugs. 2005 Apr;8(4):314-319.
Foster, Alan C. ; Chen, Chen ; Markison, Stacy ; Marks, Daniel. / MC4 receptor antagonists : A potential treatment for cachexia. In: IDrugs. 2005 ; Vol. 8, No. 4. pp. 314-319.
@article{94218502355c46baa9a02222dda106ad,
title = "MC4 receptor antagonists: A potential treatment for cachexia",
abstract = "Cachexia (involuntary weight loss) is a devastating syndrome associated with many chronic diseases including cancer, and heart, lung, kidney and liver failure. There are currently no effective treatments capable of reversing the loss of lean body mass that is believed to be a major contributor to morbidity and mortality in these chronic diseases. Recent findings strongly indicate that blockade of central melanocortin signaling through the MC4 receptor subtype attenuates cachexia. This review summarizes the evidence supporting the role of MC4 receptors in cachexia, and highlights the progress achieved in the development of small-molecule MC4 antagonists, which have recently proved to be effective in animal models of cachexia. MC4 antagonists are an attractive therapeutic approach for cachexia that may ameliorate the loss of lean body mass in cachectic patients.",
keywords = "Body-weight regulation, Cachexia, MC4 receptor, Melanocortins",
author = "Foster, {Alan C.} and Chen Chen and Stacy Markison and Daniel Marks",
year = "2005",
month = "4",
language = "English (US)",
volume = "8",
pages = "314--319",
journal = "IDrugs : the investigational drugs journal",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - MC4 receptor antagonists

T2 - A potential treatment for cachexia

AU - Foster, Alan C.

AU - Chen, Chen

AU - Markison, Stacy

AU - Marks, Daniel

PY - 2005/4

Y1 - 2005/4

N2 - Cachexia (involuntary weight loss) is a devastating syndrome associated with many chronic diseases including cancer, and heart, lung, kidney and liver failure. There are currently no effective treatments capable of reversing the loss of lean body mass that is believed to be a major contributor to morbidity and mortality in these chronic diseases. Recent findings strongly indicate that blockade of central melanocortin signaling through the MC4 receptor subtype attenuates cachexia. This review summarizes the evidence supporting the role of MC4 receptors in cachexia, and highlights the progress achieved in the development of small-molecule MC4 antagonists, which have recently proved to be effective in animal models of cachexia. MC4 antagonists are an attractive therapeutic approach for cachexia that may ameliorate the loss of lean body mass in cachectic patients.

AB - Cachexia (involuntary weight loss) is a devastating syndrome associated with many chronic diseases including cancer, and heart, lung, kidney and liver failure. There are currently no effective treatments capable of reversing the loss of lean body mass that is believed to be a major contributor to morbidity and mortality in these chronic diseases. Recent findings strongly indicate that blockade of central melanocortin signaling through the MC4 receptor subtype attenuates cachexia. This review summarizes the evidence supporting the role of MC4 receptors in cachexia, and highlights the progress achieved in the development of small-molecule MC4 antagonists, which have recently proved to be effective in animal models of cachexia. MC4 antagonists are an attractive therapeutic approach for cachexia that may ameliorate the loss of lean body mass in cachectic patients.

KW - Body-weight regulation

KW - Cachexia

KW - MC4 receptor

KW - Melanocortins

UR - http://www.scopus.com/inward/record.url?scp=19944421460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944421460&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 314

EP - 319

JO - IDrugs : the investigational drugs journal

JF - IDrugs : the investigational drugs journal

SN - 1369-7056

IS - 4

ER -